# Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data

> **NCT06392763** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 602 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Acute Lymphoblastic Leukemia (ALL)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06392763
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-03
- **Primary completion:** 2023-04-28
- **Final completion:** 2023-04-28
- **Target enrollment:** 602 (ACTUAL)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06392763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06392763, "Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06392763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*